Sabby Management, LLC
stated that they own 10% of Geovax Labs Inc (OTCMKTS:GOVX) in a Schedule 13G/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Thursday, January 4th. The investor owns 8,307,476 shares of the stock valued at $490,141. The reporting parties listed on the disclosure included Sabby Healthcare Master Fund, Ltd, Sabby Volatility Warrant Master Fund, Ltd, Sabby Management, LLC and Hal Mintz. The filing is available through Edgar at this hyperlink.
Shares of Geovax Labs Inc (GOVX) remained flat at $$0.06 during midday trading on Thursday. 80,595 shares of the stock traded hands, compared to its average volume of 719,583. The firm has a market capitalization of $4.87, a price-to-earnings ratio of -1.18 and a beta of 0.11. Geovax Labs Inc has a fifty-two week low of $0.02 and a fifty-two week high of $0.10.
Geovax Labs (OTCMKTS:GOVX) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.01) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.01). The business had revenue of $0.25 million during the quarter, compared to analyst estimates of $0.30 million. equities research analysts predict that Geovax Labs Inc will post -0.04 EPS for the current year.
Geovax Labs Profile
GeoVax Labs, Inc (GeoVax) is a clinical-stage biotechnology company. The Company is engaged in developing human vaccines against infectious diseases using its modified vaccine Ankara-virus-like particles (MVA-VLP) vaccine platform. The Company’s platform supports in vivo expression of non-infectious virus-like particles (VLPs) from the cells of the person receiving the vaccine.
Receive News & Ratings for Geovax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geovax Labs and related companies with MarketBeat.com's FREE daily email newsletter.